Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05653232 · ClinicalTrials.gov registry record · NA

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

A NA study of HCV, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
9
Study locations

NCT05653232 is a NA study of HCV that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 120 participants, below the 184-participant average among 8 other HCV trials with a reported enrollment target (35% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05653232, a NA study of HCV, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
9
Study locations

Study Summary

This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks. Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.

Conditions Studied

HCV

Interventions

  • OTHER Prophylaxis (P2W)
  • OTHER Transmit and Treat (T&T)

Study Locations (9)

California

  • University of California San Diego - La Jolla
  • Loma Linda University Health - Loma Linda

New York

  • NYU Langone Health - New York
  • Icahn School of Medicine at Mount Sinai - New York

Maryland

  • Johns Hopkins University - Baltimore

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Utah

  • University of Utah Medical Center - Salt Lake City

Virginia

  • Virginia Commonwealth University - Richmond

Wisconsin

  • University of Wisconsin, Madison - Madison

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-04-19
Est. Completion 2027-03
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05653232

The ClinicalTrials.gov registry entry for NCT05653232 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 8 other HCV trials with a reported enrollment target (35% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HCV appearing as the primary indexed condition, and to 2 interventions - of which Prophylaxis (P2W) is the first listed.

NCT05653232 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, New York, Maryland.

Frequently Asked Questions

What is clinical trial NCT05653232 about?

NCT05653232 is a clinical study titled "Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients". This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before ...

What is the current status of trial NCT05653232?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-04-19. Estimated completion is 2027-03.

What conditions does trial NCT05653232 study?

This clinical trial studies the following conditions: HCV.

What interventions are being tested in trial NCT05653232?

The interventions under investigation include: Prophylaxis (P2W) (OTHER), Transmit and Treat (T&T) (OTHER).

Who is sponsoring clinical trial NCT05653232?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05653232 being conducted?

This trial has 9 study locations across California, Maryland, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HCV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HCV

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.